Immunogenicity and safety of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and the preS2.
Arch Virol Suppl
; 4: 147-53, 1992.
Article
em En
| MEDLINE
| ID: mdl-1450683
ABSTRACT
A group of 273 health care workers, at risk of HBV infection, underwent vaccination with recombinant HBsAg produced in mammalian cells and containing protein sequences coded by both the S and pre-S2 regions (Genhevac B). Preliminary results show that a very early pre-S2 response occurred which may be useful in post-exposure prophylaxis. This observation, in addition to reduced influence by the vaccination protocol, provides grounds for optimism in spite of the fact that the efficiency spectrum of this vaccine was not superior to that of recombinant vaccines produced in yeast.
Buscar no Google
Coleções:
01-internacional
Contexto em Saúde:
2_ODS3
/
4_TD
Base de dados:
MEDLINE
Assunto principal:
Precursores de Proteínas
/
Vacinas Sintéticas
/
Vacinação
/
Vacinas contra Hepatite B
/
Hepatite B
/
Antígenos de Superfície da Hepatite B
Limite:
Adolescent
/
Adult
/
Humans
Idioma:
En
Revista:
Arch Virol Suppl
Ano de publicação:
1992
Tipo de documento:
Article